Analysis of TEM8 expression and vascular endometrial markers in TMAs.
Research type
Research Study
Full title
Analysis of TEM8 expression and its co-localisation with vascular endothelial markers in pan cancer and single cancer Tissue Micro Arrays (TMAs) by means of microscopy, immunohistochemistry and digital spatial profiling analysis.
IRAS ID
330485
Contact name
Gayle Marshall
Contact email
Sponsor organisation
Vitarka Therapeutics Ltd.
Clinicaltrials.gov Identifier
23/PR/0807, REC Reference
Duration of Study in the UK
0 years, 11 months, 28 days
Research summary
Medicines Discovery Catapult (MDC) is collaborating with Vitarka Therapeutics Ltd (Vitarka) to investigate the expression of TEM8 within the stroma of cancer tissues and other cell types.
MDC would access pan cancer Tissue Microarrays (TMAs) and seek to understand if TEM8 colocalises with vascular endothelial cells in the stroma and identify any other markers that are co-expressed in different cancer types. Microscopy techniques will be used to detect co-expression and digital spatial profiling would be carried out using the relevant proteomics and transcriptomics panels.The cancers of interests include Triple Negative Breast Cancer (TNBC), Colorectal cancer (CRC), Multi-tumour TMAs and Non-small cell Lung Cancer (NSCLC). Based on the data generated within this study, additional tumour types would be selected and analysed in the same way as part of Vitarka's the pre-clinical drug development.
Vitarka is biotech focused on the development of RNAi therapies and non-viral delivery platform technology for two validated, druggable targets as 1st line for currently untreated patient populations and 2nd line for PD-1 resistant tumours. This work will highlight potential patients that might respond to such treatments.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
23/EE/0184
Date of REC Opinion
8 Aug 2023
REC opinion
Favourable Opinion